Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.

Journal of cancer research and therapeutics - 1 Jan 2000

Shukla Pragya, Gupta Deepak, Pant Mohan Chand, Parmar Devendra

Abstract excerpt

AIMS: A major problem in cancer pharmacology is the unpredictability of the outcome of therapy, both in terms of tumor response and host toxicity. Pharmacogenetic variability associated with the drug metabolizing enzyme systems is a major determinant of variations in these outcomes. MATERIALS AND METHODS: A case-control study of 100 male cases of head and neck squamous cell carcinoma and equal number of healthy...

Topics

Adult
Aged
Carcinoma, Squamous Cell
Cytochrome P-450 CYP2D6
Genetic Predisposition to Disease
Genotype
Head and Neck Neoplasms
Humans
Male
Middle Aged
Polymorphism, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prognosis

Risk Factors

Treatment Outcome

Source

Identifiers

PMID: 22531512
DOI: 10.4103/0973-1482.95172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.PMID 22531512Read ↗

Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs.Semantic proximity Read ↗

Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.Semantic proximity Read ↗

Meta-analyses of the effect of CYP1A1 and CYP2D6 polymorphisms on the risk of head and neck squamous cell carcinoma.Semantic proximity Read ↗

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome.Semantic proximity Read ↗

Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.Semantic proximity Read ↗

Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6.Semantic proximity Read ↗

Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis.Semantic proximity Read ↗

Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.Semantic proximity Read ↗

CYP2D6 and CYP1A1 mutations in the Turkish population.Semantic proximity Read ↗

CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients.Semantic proximity Read ↗

Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.Semantic proximity Read ↗

Genetic variations and head and neck cancer risks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.